Search

Your search keyword '"Elena Kuzovatova"' showing total 3 results
Start Over Author "Elena Kuzovatova" Topic 030212 general & internal medicine
3 results on '"Elena Kuzovatova"'

1. Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations

Author

Jelena Smidt, Elena Kuzovatova, Nikoloz Chkhartishvili, Kamilla Laut, Eric Florence, Dzmitry Paduta, Dalibor Sedláček, Roxana Radoi, Brigitte Schmied, Gerd Fätkenheuer, Janos Szlavik, Matti Ristola, Fiona Mulcahy, Patrick Schmid, Leah Shepherd, Josip Begovac, Magnus Gottfredsson, Pere Domingo, Jens D Lundgren, Ole Kirk, Brygida Knysz, and Amanda Mocroft

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Sustained Virologic Response, Sexual Behavior, Immunology, HIV Infections/drug therapy, HIV Infections, Logistic regression, Anti-Retroviral Agents/therapeutic use, law.invention, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Population Groups, law, Antiretroviral Therapy, Highly Active, medicine, Immunology and Allergy, Humans, 030212 general & internal medicine, Geography, Drug Utilization/statistics & numerical data, antiretroviral treatment, HIV, Public health, Odds ratio, Middle Aged, Viral Load, 030112 virology, Confidence interval, Drug Utilization, 3. Good health, Antiretroviral Therapy, Highly Active/methods, Europe, Infectious Diseases, Transmission (mechanics), Treatment Outcome, Anti-Retroviral Agents, Cohort, Female, Viral load, Cohort study, Demography
Abstract

Objectives: We assessed differences in antiretroviral treatment (ART) coverage and virological suppression across three HIV key populations, as defined by self-reported HIV transmission category: sex between men, injection drug use (IDU) and heterosexual transmission. Design: A multinational cohort study. Methods: Within the EuroSIDA study, we assessed region-specific percentages of ART coverage among those in care and virological suppression (

Published
2018
Full Text
View/download PDF

2. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

Author

Massimo Galli, Vincent Soriano, Manuel Battegay, E. Mularska, AM Johnson, Viktar Mitsura, Bernard Hirschel, E. Simons, François Dabis, Josip Begovac, M. Gargiulo, Luigia Elzi, P. Vernazza, Thérèse Staub, Antoni Jou, Dan Turner, Fiona Mulcahy, Gatell Jm, Kamal Mansinho, G. Mateo, V. Ormaasen, Boron-Kaczmarska A. Boron-Kaczmarska, M. H. Losso, A Horban, Sonia Moreno, Rainer Weber, Christian Pradier, I. Bravo, Gianpiero D’Offizi, I. Yust, Michael Burke, Jens Nielsen, Magnus Gottfredsson, J Weber, Juergen K. Rockstroh, Juan González-Lahoz, Philippe Vanhems, N. Chentsova, G. Kyselyova, Markus Bickel, Christine Katlama, Nicola Gianotti, Irina Khromova, Roberto Esposito, Dalibor Sedláček, Gerd Fätkenheuer, Ladislav Machala, J. Kosmidis, Anders Sönnerborg, Anders Blaxhult, Francesco Mazzotta, S. Chaplinskas, Lars Østergaard, Cristina Tural, Anna Grzeszczuk, Shimon Pollack, Martin Fisher, E. Kravchenko, Marie-Luce Delforge, Claudine Duvivier, N. Vetter, Bruno Ledergerber, A. Vassilenko, Cristina Mussini, K. Kostov, E. Boffi, I. Zeltina, Danica Staneková, Pierre-Marie Girard, Robert Hemmer, L Caldeira, Robert Zangerle, Jan Gerstoft, Smidt Jelena Smidt, [No Value] Schmidt, Elżbieta Jabłonowska, M. Haouzi, G. Hassoun, P Francioli, Dénes Bánhegyi, M. Gutiérrez, Hans-Jürgen Stellbrink, Roger Paredes, A d'Arminio Monforte, O. Suetnov, T. Katzenstein, Robert Flisiak, Brygida Knysz, K. Wojcik, Jordi Puig, Baiba Rozentale, A. Gabbuti, Antonella Castagna, Olaf Degen, J van Lunzen, S. Servitskiy, D. Neau, Court Pedersen, Miłosz Parczewski, Jean-Paul Viard, Fernando Maltez, M. Kundro, D Podlekareva, Nathan Clumeck, G. Scullard, Leo Flamholc, Thomas Benfield, M. Larsen, Hansjakob Furrer, M. Mokráš, A. Thalme, M. Beniowski, I. Mazeu, G. Kutsyna, S De Wit, Peter Reiss, Vincenzo Vullo, Pere Domingo, Igor Karpov, Panagiotis Gargalianos, Ulrik Bak Dragsted, David Jilich, Elena Kuzovatova, Miriam Lichtner, E. Malolepsza, Anastasiia Kuznetsova, S. Buzunova, Matthias Cavassini, Pablo Labarga, A. B E Hansen, A. Maeland, Margaret A. Johnson, Djordje Jevtovic, J. Bruun, A Rakhmanova, Chloe Orkin, M. Pynka, V. Frolov, D. Duiculescu, AN Phillips, J Gasiorowski, Ole Kirk, V. Hadziosmanovic, P. Skinhøj, J. Tomazic, Maria A. Sambeat, R. Pristera, J. W. Goethe, G. Kronborg, Daniel Grint, Elzbieta Bakowska, L. N. Nielsen, A. Rakmanova, Claudio Arici, C. Taibi, Matti Ristola, J. M. Rodriguez, Miró Jm, Amanda Mocroft, H. Trocha, Jd Lundgren, Hila Elinav, Clifford Leen, E. Montesarchio, Eric Florence, Linos Vandekerckhove, Adriano Lazzarin, Jose Medrano, J. Perdios, Manuela Doroana, Brian Gazzard, Antonio Chirianni, Annalisa Ridolfo, A. Antinori, Johannes R. Bogner, Kai Zilmer, G. Xylomenos, Bonaventura Clotet, and H. Sambatakou

Subjects
Cart, Rate ratio, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, parasitic diseases, medicine, Pharmacology (medical), 030212 general & internal medicine, Poisson regression, 0303 health sciences, 030306 microbiology, business.industry, Health Policy, Stavudine, medicine.disease, Confidence interval, 3. Good health, Infectious Diseases, HIV-positive people, Cohort, symbols, Lipodystrophy, business, Demography, medicine.drug
Abstract

OBJECTIVES: The long-term side effects of stavudine (d4T) led to recommendations in 2009 to phase out use of this drug. We aimed to describe temporal patterns of d4T use across Europe. METHODS: Patients taking combination antiretroviral therapy (cART) in EuroSIDA with follow-up after 1 January 2006 were included in the study. cART was defined as d4T-containing [d4T plus at least two other antiretrovirals (ARVs) from any class] or non-d4T-containing (at least three ARVs from any class, excluding d4T). Poisson regression was used to describe temporal changes in the prevalence of d4T use and factors associated with initiating d4T. RESULTS: A total of 5850 patients receiving cART on 1 January 2006 were included in the current analysis, rising to 7768 patients on January 1 2013. During this time, the prevalence of d4T use fell from 11.2% to 0.7%, with an overall decline of 19% per 6 months [95% confidence interval (CI) 19-20%]. d4T use declined fastest in Northern Europe [26% (95% CI 23-29%) per 6 months], and slowest in Eastern Europe [17% (95% CI 16-19%) per 6 months]. In multivariable Poisson regression models, new d4T initiations decreased by 14% per 6 months [adjusted incidence rate ratio (aIRR) 0.86; 95% CI 0.80-0.91]. Factors associated with initiating d4T were residence in Eastern Europe (aIRR 4.31; 95% CI 2.17-9.98) versus other European regions and HIV RNA > 400 copies/mL (aIRR 3.11; 95% CI 1.60-6.02) versus HIV RNA < 400 copies/mL. CONCLUSIONS: d4T use has declined sharply since 2006 to low levels in most regions; however, a low but persistent level of d4T use remains in Eastern Europe, where new d4T initiations post 2006 are also more common. The reasons for the regional differences may be multifactorial, but it is important to ensure that all clinicians treating HIV-positive patients are aware of the potential harmful effects associated with d4T.

Published
2015
Full Text
View/download PDF

3. Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015

Author

Thérèse Staub, Robert Zangerle, Tatiana Trofimova, Elena Kuzovatova, Anders Blaxhult, Cristina Mussini, Leah Shepherd, Kamilla Laut, Igor Karpov, Fernando Maltez, Dorthe Raben, Roxana Radoi, Kai Zilmer, Miłosz Parczewski, Jens D Lundgren, Amanda Mocroft, Helen Kovari, Hila Elinav, Marcelo H. Losso, Nikoloz Chkhartishvili, Ole Kirk, and Malgorzata Inglot

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Continuity of patient care, Epidemiology, Europe, HIV infection, Surveillance, Treatment outcome, Public Health, Environmental and Occupational Health, Virology, Sustained Virologic Response, Human immunodeficiency virus (HIV), HIV Infections, medicine.disease_cause, Logistic regression, Odds, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Antiretroviral treatment, Medicine, Humans, 030212 general & internal medicine, Treatment Failure, Healthcare Disparities, business.industry, Environmental and Occupational Health, Middle Aged, Viral Load, 030112 virology, Confidence interval, 3. Good health, CD4 Lymphocyte Count, Anti-Retroviral Agents, Western europe, RNA, Viral, Female, Public Health, business, Demography, Research Article
Abstract

Background: Direct comparisons between countries in core HIV care parameters are often hampered by differences in data collection. Aim: Within the EuroSIDA study, we compared levels of antiretroviral treatment (ART) coverage and virological suppression (HIV RNA

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results